WW domain-containing oxidoreductase: a candidate tumor suppressor

Trends in Molecular Medicine

Volumn 13, Issue 1, 2007, Pages 12-22

  Chang, Nan Shan ^a,b   Hsu, Li Jin ^a   Lin, Yee Shin ^a   Lai, Feng Jie ^a   Sheu, Hamm Ming ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; HYALURONIDASE; OXIDOREDUCTASE; PROTEIN P53; PROTEIN P73; PROTEIN WWOX; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; WWOX GENE;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; GENE COMPONENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; HYALURONOGLUCOSAMINIDASE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OXIDOREDUCTASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33845879138     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.11.006     Document Type: Article

References (75)

1. Bednarek A.K., et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60 (2000) 2140-2145
2. Ried K., et al. Common chromosomal fragile site FRAD16D sequence: identification of the FOR gene spanning FRAD16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 9 (2000) 1651-1663
3. Chang N.-S., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 276 (2001) 3361-3370
4. Chang N.-S., et al. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem. Pharmacol. 66 (2003) 1347-1354
5. Watanabe A., et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res. 63 (2003) 8629-8633
6. Mahajan N.P., et al. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res. 65 (2005) 10514-10523
7. Lokeshwar V.B., et al. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 65 (2005) 7782-7789
8. Sze C.-I., et al. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease. J. Biol. Chem. 279 (2004) 30498-30506
9. Chang N.-S., et al. 17β-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene 24 (2005) 714-723
10. Krummel K.A., et al. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer 34 (2002) 154-167
11. Sudol M., and Hunter T. NeW wrinkles for an old domain. Cell 103 (2000) 1001-1004
12. Hu H., et al. A map of WW domain family interactions. Proteomics 4 (2004) 643-655
13. Sudol M., et al. WW or WoW: the WW domains in a union of bliss. IUBMB Life 57 (2005) 773-778
14. Lu K.P. Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem. Sci. 29 (2004) 200-209
15. Butterfield D.A., et al. Pin1 in Alzheimer's disease. J. Neurochem. 98 (2006) 1697-1706
16. Oppermann U.C., et al. Forms and functions of human SDR enzymes. Chem. Biol. Interact. 130-132 (2001) 699-705
17. Yan S.D., and Stern D.M. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-β peptide alcohol dehydrogenase (ABAD). Int. J. Exp. Pathol. 86 (2005) 161-171
18. Chang N.-S., et al. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J. Biol. Chem. 278 (2003) 9195-9202
19. Aqeilan R.I., et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4401-4406
20. Chen S.T., et al. Light-induced retinal damage involves tyrosine 33 phosphorylation, mitochondrial and nuclear translocation of WW domain-containing oxidoreductase in vivo. Neuroscience 130 (2005) 397-407
21. Chang N.-S. A potential role of p53 and WOX1 in mitochondrial apoptosis. Int. J. Mol. Med. 9 (2002) 19-24
22. Bednarek A.K., et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 61 (2001) 8068-8073
23. Jin C., et al. PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. Biochem. Biophys. Res. Commun. 341 (2006) 784-791
24. Chen S.T., et al. Expression of WW domain-containing oxidoreductase WOX1 in the developing murine nervous system. Neuroscience 124 (2004) 831-839
25. Lai F.J., et al. WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin. Cancer Res. 11 (2005) 5769-5777
26. Nunez M.I., et al. WWOX protein expression in normal human tissues. J. Mol. Histol. 31 (2006) 115-125
27. Chang N.-S., et al. WOX1 is essential for TNF-, UV light-, staurosporine-, and p53-mediated cell death and its tyrosine 33 phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J. Biol. Chem. 280 (2005) 43100-43108
28. Fabbri M., et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15611-15616
29. Qin H.R., et al. A role for the WWOX gene in prostate cancer. Cancer Res. 66 (2006) 6477-6481
30. Cantor J.P., et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int. J. Cancer 120 (2007) 24-31
31. Sbrana I., et al. Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer. Genes Chromosomes Cancer 45 (2006) 429-436
32. Richards R.I. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 17 (2001) 339-345
33. Hsu H.C., et al. Tumor necrosis factor ligand-receptor superfamily and arthritis. Curr. Dir. Autoimmun. 9 (2006) 37-54
34. Aqeilan R.I., et al. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2γ transcription factor. Cancer Res. 64 (2004) 8256-8261
35. Aqeilan R.I., et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 65 (2005) 6764-6772
36. Ludes-Meyers J.H., et al. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 23 (2004) 5049-5055
37. Bretscher A., et al. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3 (2002) 586-599
38. Ludes-Meyers J.H. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet. Genome Res. 100 (2003) 101-110
39. Matsuyama A., et al. Common fragile genes. Eur. J. Histochem. 48 (2004) 29-36
40. Ishii H., and Furukawa Y. Alterations of common chromosome fragile sites in hematopoietic malignancies. Int. J. Hematol. 79 (2004) 238-242
41. O'Keefe L.V., and Richards R.I. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett. 232 (2006) 37-47
42. Iliopoulos D., et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 232 (2006) 27-36
43. Smith D.I., et al. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett. 232 (2006) 48-57
44. Yakicier M.C., et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20 (2001) 5232-5238
45. Driouch K., et al. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21 (2002) 1832-1840
46. Kuroki T., et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 62 (2002) 2258-2260
47. Yendamuri S., et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 63 (2003) 878-881
48. Kuroki T., et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin. Cancer Res. 10 (2004) 2459-2465
49. Aqeilan R.I., et al. Loss of WWOX expression in gastric carcinoma. Clin. Cancer Res. 10 (2004) 3053-3058
50. Pimenta F.J., et al. Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int. J. Cancer 118 (2006) 1154-1158
51. Ishii H., et al. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol. Cancer Res. 1 (2003) 940-947
52. Thavathiru E., et al. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol. Carcinog. 44 (2005) 174-182
53. Ishii H., et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites. Mol. Cancer Res. 3 (2005) 130-138
54. Pluciennik E., et al. WWOX - the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur. J. Surg. Oncol. 32 (2006) 153-157
55. Paige A., et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11417-11422
56. Zhou Y., et al. Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer. J. Huazhong Univ. Sci. Technolog. Med. Sci 25 (2005) 162-165
57. Gourley C., et al. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int. J. Oncol. 26 (2005) 1681-1689
58. Iliopoulos D., et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24 (2005) 1625-1633
59. Guler G., et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100 (2004) 1605-1614
60. O'Keefe L.V., et al. FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila. Oncogene 24 (2005) 6590-6596
61. Lippens S., et al. Death penalty for keratinocytes: apoptosis versus cornification. Cell Death Differ. 12 (2005) 1497-1508
62. Candi E., et al. The cornified envelope: a model of cell death in the skin. Nat. Rev. Mol. Cell Biol. 6 (2005) 328-340
63. Yang G., et al. Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J. Invest. Dermatol. 126 (2006) 2490-2506
64. Diepgen T.L., and Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 61 (2002) 1-6
65. Van Laethem A., et al. The sunburn cell: regulation of death and survival of the keratinocyte. Int. J. Biochem. Cell Biol. 37 (2005) 1547-1553
66. Nunez M.I., et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 5 (2005) 64
67. Csoka T.B., et al. Hyaluronidases in tissue invasion. Invasion Metastasis 17 (1997) 297-311
68. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 4 (2004) 528-539
69. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathol. Biol. (Paris) 53 (2005) 372-382
70. Csoka A.B., et al. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 20 (2001) 499-508
71. St Croix B., et al. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett. 131 (1998) 35-44
72. Beech D.J., et al. Expression of PH-20 in normal and neoplastic breast tissue. J. Surg. Res. 103 (2002) 203-207
73. Chang N.-S. Transforming growth factor-β1 blocks the enhancement of tumor necrosis factor cytotoxicity by hyaluronidase Hyal-2 in L929 fibroblasts. BMC Cell Biol. 3 (2002) 8
74. Nunez M.I., et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res. Treat. 89 (2005) 99-105
75. Rossi M., et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 12753-12758